Promising Results of Cadonilimab and Pulocimab in Treating Resistance in Lung Cancer Akeso Inc. presents encouraging clinical study results for cadonilimab and pulocimab in treating IO-resistant non-small cell lung cancer, showcasing new hope for patients.

Promising Results of Cadonilimab and Pulocimab in Treating Resistance in Lung Cancer #Hong_Kong #Akeso #Cadonilimab #Pulocimab